Scarica l'app Stockscreener
6.18
3.34%
0.20
Dopo l'orario di chiusura:
2.66
-3.52
-56.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.98
Aprire:
$6.13
Volume 24 ore:
155.73K
Relative Volume:
4.29
Capitalizzazione di mercato:
$11.15M
Reddito:
-
Utile/perdita netta:
$-47.73M
Rapporto P/E:
-0.4292
EPS:
-14.3996
Flusso di cassa netto:
$-13.18M
1 W Prestazione:
-2.06%
1M Prestazione:
-22.89%
6M Prestazione:
-40.63%
1 anno Prestazione:
-69.10%
Intervallo 1D:
$5.50
$6.74
Intervallo di 1 settimana:
$4.9101
$6.74
Portata 52W:
$4.9101
$34.25
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, PSNYW, GOODO, SHMD, CHAD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.395 | 1.79B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
4.14 | 698.19M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
19.67 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.23 | 226.24M | 52.15M | -21.46M | 0 | -0.4675 |
CHAD
Direxion Daily CSI 300 China A
|
8.07 | 197.39M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
EBITDA per share of GT Biopharma Inc – FWB:OXI - TradingView
symbol__ Stock Quote Price and Forecast - CNN
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsSuperTrend - siam.in
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure - TipRanks
GTBP stock holds steady as GT Biopharma advances TriKE cancer pipeline - ad-hoc-news.de
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - Eastern Progress
GT Biopharma Inc (NASDAQ: GTBP) Share Price, GTBP Stock News, GTBP Share Price & Updates - Kalkine
Stock Quotes, Business News and Data from Stock Markets | MSN Money - MSN
GTBP Q1 2026 Earnings: EPS Misses Estimates as Stock Drops 3.72%Dividend Cut Risk - vinanet.vn
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan - TipRanks
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan
GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million - scanx.trade
Gt Biopharma Reports Second Quarter 2026 Financial Results - TradingView
GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026 - TradingView
GT Biopharma Reports Second Quarter 2026 Financial Results - The Manila Times
GT Biopharma (GTBP) cuts net loss but flags going concern and Nasdaq risk - Stock Titan
GTBP Q1 2026 Earnings: Wider Loss Misses Estimates as Clinical Investment ContinuesEarnings Stability Report - vinanet.vn
GT Biopharma Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma Inc (GTBP) Stock News Today - TradingKey
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - SmallCap Asia
GTBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GTBP Q1 2026 Earnings: Wider Loss Misses Estimates as Clinical-Stage Pipeline AdvancesEstimate Accuracy - vinanet.vn
GT Biopharma (GTBP) Slips 4.65% to $0.29, Testing Critical Support Near $0.28Trend Reversal Picks - dars.gov.et
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GTBP Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentProfit Growth Outlook - vinanet.vn
GT Biopharma Edges Higher as Biotech Sector Sees Renewed Interest — GTBP Hovers Near Key LevelsSmart Beta Flow - po-news-eg.net
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GT Biopharma Inc (GTBP) Cash Flow - TradingKey
GT Biopharma Inc (GTBP) Income Statement - tradingkey.com
GTBP|GT Biopharma Inc|Price:0.335|Chg%:+0.011 - TradingKey
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GTBP|GT Biopharma Inc|Price:0.310|Chg%:-0.011 - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GTBP|GT Biopharma Inc|Price:0.324|Chg%:-0.011 - TradingKey
GT Biopharma Shares Decline 3.25% as Stock Tests Key Support at $0.30Zero Gamma Level - vinanet.vn
GT Biopharma(GTBP) Stock Options Chain | Quotes & News - Moomoo
GT Biopharma, Inc. Revenue Breakdown – NASDAQ:GTBP - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to earnings forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to earnings forward of GT Biopharma Inc – SWB:OXIA - TradingView
GT Biopharma (GTBP) Declines 3.96% as Stock Nears Critical $0.32 Support LevelVolume Weighted Price - vinanet.vn
Immunotherapy Breakthroughs Propel Clinical Momentum Ahead of ESMO Congress - Baystreet.ca
GTBP Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Ongoing Pre-Revenue StageTrough Earnings Signal - vinanet.vn
GT Biopharma (GTBP) Slides to $0.42 Amid Continued Selling PressureRetracement Entry - dars.gov.et
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - Newswire Canada
GTBP News | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):